NextCure, Inc's Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
Portfolio Pulse from Benzinga Newsdesk
NextCure, Inc. (NASDAQ:NXTC) has announced the presentation of Phase 2 clinical data demonstrating clinical benefit in patients with advanced, PD-1 axis inhibitor refractory non-small cell lung cancer (NSCLC) treated with a combination regimen of NC318, a Siglec-15 (S15) monoclonal antibody (mAb), and pembrolizumab, an anti-PD-1 antibody.
September 12, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NextCure's Phase 2 clinical data shows positive results for their combination treatment for NSCLC, which could potentially lead to increased investor interest.
The positive results from the Phase 2 clinical trial indicate that NextCure's combination treatment for NSCLC is effective. This could potentially lead to increased investor interest in the company, as it demonstrates progress in their research and development efforts. This could potentially lead to a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100